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INTRODUCTION 
Counterfeiting is a substantial problem that is growing 
worldwide and affects both developed and less developed 
countries.
1 
Counterfeit products are illegal, low priced 
and often of lower quality than their originals.
2
 When it is 
medicines being counterfeited, this is not only damaging 
to the pharmaceutical industries but also constitutes a 
significant threat to public health.
3
 The European 
Commission estimated that counterfeiting in general 
represents around 5–7% of world trade, and around 15% 
of the global medicine supply chain could be counterfeit.
4
 
The incidence of counterfeit medicine (CFM) varies 
based on each country’s regulatory and enforcement 
system. Poor and developing countries with weak 
regulatory and enforcement systems have higher 
percentages of CFM.
1,5
 Developed countries are less 
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vulnerable to CFM and are considered properly regulated 
with well-controlled systems, yet several cases have been 
discovered within their legal pharmaceutical distribution 
chains.
6
 
The most common factors that encourage counterfeiters 
to produce CFM are: lack of legislation prohibiting 
counterfeiting of medicine; weak or minimum 
enforcement of laws and disciplinary actions; the high 
cost of branded medicine; and a shortage of medicine 
supplies.
1,5,7
 
CFMs play a major role in destroying the public’s trust in 
the healthcare team; the safety and efficacy of 
pharmaceutical products; government and regulatory 
authorities in controlling the availability of CFM.
8-10
 
Moreover, ignorance of the risks and attributes of CFMs 
increases the vulnerability towards CFM use, causing 
lower detection and reporting rates for counterfeits.
9
 
The problem of CFM continues and the crisis of medicine 
shortages is still present, however, currently the 
economic, political, governmental and regulatory 
situations of each country, add to the reasons why CFMs 
are more readily available in some countries more than 
others.
1
 For example, in Lebanon, a related study 
explored the availability of CFM in various households in 
Lebanon and found the extent of CFM to range from 3% 
in Mount Lebanon (ML) to 12% in the Bekaa and South 
of Lebanon.
11 
This study is part of a bigger research programme based 
on the mixed-methods methodology
 
that included points 
of interaction between the qualitative (sub-study) and 
quantitative (bigger study) components, using the 
explanatory sequential design.
12
 The data in this design 
are gathered sequentially in two phases. Phase one (the 
bigger study) used quantitative research that collected 
and analysed data from questionnaires.
11,13
 Phase two is 
this study (sub-study) that used qualitative research 
(focus groups) to explain the findings of the 
questionnaires in phase one.
11,12
  
Focus groups (FG) and interviews are both useful 
qualitative methods.
14,15
 FG allow participants to listen to 
the opinion of others, gather views of several people 
simultaneously and understand the issues that would not 
be possible to generate without the interaction produced 
from group discussions.
16
 FG were used for convenience 
since they yield a large amount of data in a short period 
of time, while the one to one interviews would require 
more time.
14,15
  
There have been limited studies that used FG to explore 
perceptions about CFM with the public or pharmacists.
17
 
A study in Sudan determined the factors related to CFM 
purchases using interviews, and another in Lao People’s 
Democratic Republic (PDR) explored the knowledge and 
perceptions of medicine quality using interviews and 
FG.
1,17
 Both concluded that lack of knowledge, high 
prices and unaffordability of medicines have a major role 
in increasing the likelihood of the public using counterfeit 
or low quality medicine.  
An extensive review of the literature showed that 
qualitative research exploring the public and pharmacist 
experiences, views and beliefs towards CFM is lacking.
13
 
The aim of the study was to explore the experiences, 
views and beliefs of the public and pharmacists towards 
CFM. 
METHODS 
This study is descriptive and is based on phase two of a 
mixed-methods methodology, using the explanatory 
sequential design. The study used FG as the qualitative 
method to explore the general public and pharmacists’ 
experiences, views and beliefs towards CFM. Phase one 
of the study used questionnaires that assessed 849 
members of the public and 223 practising pharmacists on 
awareness and views towards CFM.
11,13
 The results of 
phase one showed that the questionnaire did not provide 
sufficient information about the components of people’s 
beliefs and perceptions towards CFM. Therefore, a 
qualitative research was necessary to explain and build on 
the findings of phase one.
11,12
  
In order to ensure rigour, trustworthiness, transparency, 
and integrity of the findings, the methods required the 
following: 
 Triangulation: the results of phase two illuminated 
the different perspectives towards CFM problems 
identified in phase one;
12,18
 
 Clarification: the results of the quantitative method 
(phase one) using a qualitative method (FG);
12,18
 
 Informed design: the FG method was based on the 
findings of the questionnaires, as these provided 
information from a large sample of the public about 
their experiences, views and beliefs of CFM;
12,18
 
 Peer debriefing, the researchers discussed the 
methodological process with knowledgeable peers on 
qualitative research on continuous basis.
12,18
 
 Participants’ validation, on completion of the study 
the findings were checked with participants 
(pharmacists only, since the public were difficult to 
trace back), meeting the diachronic reliability 
requirements of the findings, two years after the 
completion of the study.
12,18
 
The results of phase one were adopted using the 
explanatory sequential design process for developing the 
semi-structured guideline questions, for both the public (7 
open-ended questions) (Table 1) and pharmacists (8 
open-ended questions) (Table 2). Follow-up questions 
were asked to learn more, and probe about topics that 
participants brought up. 
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Table 1: Guideline questions for public focus group. 
No. Question 
1. 
What do you know about CFM* (Define it)? 
(K)** 
2. 
How can you differentiate/ identify between 
counterfeit and non-counterfeit? (K & A
+
) 
3. 
Why do people buy counterfeit 
medicine/products? (A) 
4. 
Who is responsible for the availability of 
counterfeit meds in the market? (A) 
5. 
 
If you discovered the medicine you have is 
counterfeit, what would you do?  
Who would you contact? (K & A) 
6. How would you avoid buying CFM? (K & A) 
7. 
What are the penalties for selling/dealing with 
CFM? Is there a law? (K & A) 
CFM=Counterfeit Medicine, (K)**=knowledge, (A+)= Attitude 
(beliefs, views & experiences). 
Table 2: Guideline questions for pharmacist focus 
group. 
No. Question 
1. How would you define CFM*? (K)** 
2. 
How would you differentiate CFM from 
original? (K) 
3. 
What measures are you taking to minimize the 
risk of carrying CFM in your pharmacies? (K 
& A
+
) 
4. 
What is your opinion of other pharmacists who 
deal with CFM? Are you aware of any? (A) 
5. 
How is the hologram helping the pharmacist 
differentiate between medicines? (A) 
6. 
Who is responsible for the availability of CFM 
in Lebanon? (A) 
7. 
8. 
Are you aware of a law related to CFM in 
Lebanon? (K & A) 
How would you report a CFM? (K & A) 
*CFM = Counterfeit Medicine, (K)**= Knowledge, (A+)= 
Attitude (beliefs, views & experiences) 
Sample  
This study was conducted in Lebanon using two public 
FG with participants from different backgrounds, and two 
FG for pharmacists from different pharmacy settings. 
Public recruitment 
Two schools in ML were contacted for permission to use 
their sites. Schools were considered a convenience 
sampling method since they offered easy access to 
members of the public.
19
 The convenience sample of 
participants was chosen based on their visits to the 
principals’ offices. The principals were provided with the 
following exclusion criteria; any individual who 1) was 
younger than 18 years old, 2) was not living in Lebanon, 
3) did not approve of audiotaping the meeting, 4) not 
willing to sign the consent form. The principals’ 
assistants asked each person if he/she would be interested 
in participating in the study. Those willing to participate 
were asked to register their names on a list with the 
assistant. Once the date was set, they were contacted and 
informed of the set times, and those able to attend were 
present. 
Pharmacists’ recruitment 
The recruitment of pharmacists used the snowball 
approach since the population was hard to reach, or 
recruit
 
due to the sensitivity of the topic, and in order to 
avoid embarrassing or coercing pharmacists not willing 
to participate.
19
 The inclusion criterion was any 
pharmacist practising in Lebanon.
20
 The exclusion criteria 
were pharmacists not living in Lebanon, who did not 
approve of using the audiotape during the meeting, and 
not willing to sign the consent form. Once the names 
were available, each pharmacist was contacted by 
telephone to explain the purpose behind the FG meetings. 
The call was followed by a confirmation email. 
Data collection  
The FG took place in the period between April to June 
2014. Before starting each meeting, the moderator 
reviewed the consent form with participants and 
encouraged questions before signing the form. At the end 
of the meeting participants were given a demographic 
questionnaire to complete, and the moderator’s contact 
information for any additional questions. 
The primary author acted as the moderator for all FG, 
with the same note-taker. Debriefing and observation 
discussions took place after each meeting between the 
moderator and note-taker. 
Data analysis 
The discussions of the public and pharmacists’ FG were 
transcribed, read and reviewed for each group. The 
analysis was performed by the inductive qualitative 
method followed by a structured process combining 
description and interpretation of the data.
19,21
 The 
reflexivity of the researchers was addressed by the 
objectivity of the results of phase one and the research 
question, independently of the researcher’s background, 
motives and perspectives. Each FG was analysed 
separately and then together.
19,21
 The analytical method 
used was thematic/category analysis as described by 
Kitzinger and Barbour.
21
 With this method a theme is 
developed based on capturing something important in 
relation to the researched topic, irrespective of the 
number of persons who referred to it.
19
 The public 
participants were considered aware of the meaning of 
CFM, if they said it was not the original, fake, or 
anything related. For pharmacists, the WHO definition 
was used as a reference.
22
 From the FG transcripts, 
meanings were interpreted, grouped and labelled with a 
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code. The codes were compared and formed into themes 
and subthemes.
18,19,21,23
 The interpretation of data was 
based on the ―intensity of comments‖, ―specificity of 
comments‖, ―internal consistency‖ and the ―big ideas‖ in 
link with the research question.
14
 The validity of the 
interpretation is linked to the triangulation method 
mentioned above to minimize distortion.
18,19
 The relevant 
quotes were used to support a theme or an observation. 
RESULTS 
The duration of the discussions for the four FG was 
between 100-120 minutes. 
Public FG 
The total number of public participants was 23. Their age 
ranged between 30 and 60, and 21 were female. Slightly 
more than one third of participants were between 31- 40 
years old. The majority had a university degree, and lived 
in the ML region. Lack of awareness dominated the 
discussion, mixed with helplessness and mistrust in the 
system.  
Five main themes emerged from the two public FG 
discussions detailed in Table 3 with related quotes. 
Table 3: Themes and subthemes developed from the two public focus groups. 
Themes and Sub themes  Quotes used during the focus group discussions 
Awareness   
1. Defining counterfeit medicine  
―I don’t really know….‖ 
―I would say the one with the different name is fake and the different 
composition is a copy‖ 
2. Identifying counterfeit medicine  
―I’m not sure how to tell the difference, honestly.‖  
―I don’t know how to differentiate, as we don’t think we have the necessary 
knowledge/information.‖ 
3. Counterfeit medicine reporting 
System  
―There’s no point of reference or particular authority to file complaints to.‖ 
―…we also aren’t in the habit of reporting abuse or incidents of being 
deceived by pharmaceutical companies and their products…‖ 
―If I got CFM, I would go back to the pharmacy and tell them about it.‖ 
II. Trust towards   
1. The system  
 
―…it is the responsibility of the MoPH* and the OPL** to send medicine to 
laboratories to test it and make sure it is the original product and is not 
harmful…‖ 
―… I shouldn’t be the one discovering that I have fallen victim to CFM+. Just 
like in any other country, someone else’s full-time job (MoPH)…‖ 
―… I believe it’s not out of the question that pharmaceutical companies 
themselves are counterfeiting medicine to get rid of their stock…‖. 
2. Pharmacists  
“I would say the first person to blame is the pharmacist. I think pharmacists 
are always aware that a medicine is counterfeit when they are selling it to 
people.‖ 
―I don’t think enough effective measures have been taken, to be honest. They 
stopped one pharmacy, but they didn’t put together a plan to punish others.‖ 
III. Corruption  
―… Fighting corruption is an immense, large-scale project, actually. There is a 
lot of corruption and ―freedom‖ at the port, there are groups who don’t adhere 
to standards and do whatever they want over there.‖  
―Because this is Lebanon. There is a lot of corruption. The government is 
corrupt. There are many loopholes and some people have immunity. They can 
do whatever they want.‖ 
IV. Locus of control   
1. Internal control   
a. Lack of knowledge 
―They either don’t know about the availability of CFM, or they do but neglect 
it, since CFM is usually cheaper.‖ 
―… a lot of people lack the necessary knowledge … to know what they’re 
taking.‖  
―Two indicators can help one know whether a medicine is good or bad: we 
either don’t get better at all, or suffer from side effects: getting poisoned or 
even dying.‖ 
2. External control   
a. Worries ―We take the medicine and pray to God we wouldn’t die.‖ 
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Themes and Sub themes  Quotes used during the focus group discussions 
b. Financial concern 
―Financial reasons have a role, too. The price of original medicine determines 
the decision to buy CFM‖ 
―Some people need to think about money nowadays, though. Not everyone 
can afford the luxury of expensive medical services, especially if they have 6 
or 7 children.‖ 
“There is a market because people can’t afford the real thing…‖ 
3. Political Instability 
―We have a lot of other things on our plate and barely have time to even think 
about this.‖  
―… undo all political ties this might have to any political party. Politics and 
health should be separated.‖ 
V. Overcoming counterfeit medicine  
1. Education  
―To limit counterfeiting, awareness is key. It would be creating a barrier for 
people who are counterfeiting …‖ 
―Media … conferences … This focus group has helped us a lot…word of 
mouth, we talk, we discuss, we get more information, we become aware.‖ 
2. Responsibility and accountability  
―… If importers are held accountable and are asked to acquire all the 
necessary forms and signatures, that would reduce the possibility of the 
presence of counterfeit medicine drastically.‖ 
―There should be forms and certificates and sustainable supervision that 
doesn’t only hold people accountable once a year, but consistently checks for 
quality and adherence to international standards and local regulations.‖ 
3. Laws and regulations  
―There should be clear laws—which many of them are present—but lack an 
organized mechanism to be applied.‖ 
―There should be penalties and organized measures to penalize the ones who 
counterfeit medicine or those willingly involved in the process.‖ 
*Ministry of Public health, ** Lebanese Order of Pharmacists, +Counterfeit medicine. 
Table 4: Themes and subthemes developed from the two pharmacists’ focus groups. 
Themes and sub themes  Quotes used during the focus group discussions 
I. Awareness  
―They might be all aware that there are CFM+, but many, especially those 
who don’t deal with them, know nothing about CFM, because I’ve asked 
some and they all said they knew nothing about CFM. They know ―of‖ them, 
but as they had never been visited by anyone nor been in a situation, they 
knew very little.‖ 
―No one can work in the field and not know. Because if one doesn’t know 
and suddenly have the counterfeit drugs in their pharmacies, how will they be 
able to stop it?‖ 
―Any medicine that’s not coming from the company itself. Anyone can sell it 
to you. It doesn’t have any effect on the patient maybe, so it’s something 
illegal you are dealing with. It may cause harm to people, including the 
pharmacist.‖ 
1. Prevalence and extent  
―These drugs are mainly available where the borders are more open, for 
example in the North and in the South. But they are also present and active in 
ML. I don’t know about Beirut, though.‖  
―… They are available also in Beirut…‖ 
2. Identifying counterfeit medicine  
―It’s usually through the patient’s response.‖ 
―They asked us how come you bought CFM. We said how were we supposed 
to know it’s counterfeit? We got it from a legal source.‖ 
3. Counterfeit medicine reporting 
System  
―…There is no official reporting system … There is no regulatory agency that 
takes feedback from the market.‖ 
―When we have counterfeit products and we discover they are counterfeit 
because we bought them. What do we do? Who do we call? Would the 
product be paid back?‖ 
II. Reasons for availability of counterfeit medicine  
1. Pharmacists   
a. Business and profit  
―…. It’s a business.‖ 
―…So some pharmacists may look at this from a profit perspective and may 
want to have their hands on such products because let’s face it... It may be a 
form of profit for the pharmacists dealing with it.‖ 
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Themes and sub themes  Quotes used during the focus group discussions 
b. Professional experience  
―…. I have asked multiple pharmacists, they all agreed that they have been 
visited 10 or 15 years ago by people selling CFM and they have had to refuse 
more than once.‖ 
2. Medicine shortages  
―This is what they’re taking advantage of…drugs in shortage … and drugs 
that are really expensive. If … your medicine costs more than 100,000 
Lebanese liras, (around USD 66) and someone pops up saying they have the 
same product for USD 5 … You buy the USD 5 product and you sell it for 
USD 50. Plenty of people or pharmacists do it…‖  
3.    Demand 
 
―This is the problem… the rest of the population who are looking to get 
medication for cheaper prices, which is their right knowing the financial 
situation in the country…‖ 
―No, not all are aware. Some are not, some don’t care.‖ 
4.    Control 
 
―Ministry should be responsible for screening CFM but that’s non-existent.‖ 
―A pharmacist is not supposed to check for CFM after having received a 
shipment of products from a supposedly respectable, trustworthy 
pharmaceutical company.‖ 
III. Trust towards 
  
1. The system  
―…The MoPH*, I’m not supposed to be doing their work. I should be feeling 
a little safe that this product has been checked and is safe because it’s been 
through a safety check process in the country.‖ 
―… there is no trust in our legislative system …‖ 
Pharmacists 
 
―The scandals are destroying the image of pharmacists. The problem is, it 
does not highlight the source of CFM, or drug supply chain, but only accuses 
pharmacists …‖ 
―…I think we are at risk of losing our status…‖ 
IV. Corruption 
 
―… look at the people who are bringing this kind of medication. They are all 
backed up by a politician or somewhere higher up. It’s always like that. And 
by the way, without naming the company, the company that was bringing 
CFM is a money laundering company.‖ 
V. Overcoming counterfeit medicine 
  
Central laboratory 
 
―I think also the MoPH should have a central lab to test drugs. Our role lies in 
refusing to buy or get some drugs from wholesalers.‖ 
―… I think also the MoPH should have a central lab to test drugs...‖ 
1. Dedicated pharmacists  
 
―So I guess as pharmacists, our role is very important on a day-to-day basis. 
We are solo workers. No one is backing us up.‖ 
Education 
 
―… I think it is important that us pharmacists need to increase awareness for 
those people. It is one of our responsibilities which we need to also address at 
a certain point.‖ 
2. Laws and regulations 
―We need to have not just laws, because we might have laws saying vague 
sentences like there should be a pharmacist in the MoPH, but what is the role 
of the pharmacist in the MoPH? We do not have an agreement on the roles. 
Who should be responsible? The OPL**, the MoPH let’s say who should be 
responsible. But how should each institution be responsible? In what way?...‖ 
Pharmacists 
 
―The scandals are destroying the image of pharmacists. The problem is, it 
does not highlight the source of CFM, or drug supply chain, but only accuses 
pharmacists …‖ 
―…I think we are at risk of losing our status…‖ 
+ Counterfeit medicine, *Ministry of Public health, ** Lebanese Order of Pharmacists. 
 
Pharmacists FG 
The total number of participants was 13. Their age ranged 
between 26 and 60, 11 were females, and two thirds were 
between 26-30 years old. Participants were mostly from, 
and practising in, ML and Beirut. Five worked with 
pharmaceutical companies, five in community, two in 
hospitals and one in both academia and community. They 
were motivated to discuss and share their concerns about 
CFM with other colleagues for the first time. Frustration 
and anger dominated the discussion. These emotions 
were associated with the perceived financial pressures 
and lack of professional ethics among pharmacists who 
deal with CFM. 
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Five main themes emerged from the two pharmacist FG 
discussions detailed in Table 4 with related quotes. 
Common themes between the public and pharmacists 
FG  
Awareness 
The discussions demonstrated a gap in participants’ 
awareness towards CFM: 1) Defining CFM; the majority 
of public participants were not able to define or provide a 
meaning to CFM, and either gave false definitions, or did 
not know. Pharmacist participants were able to define 
CFMs and were therefore considered aware of CFM. 2) 
Identifying CFM; a few of public participants were 
slightly knowledgeable and referred to the hologram, due 
to recent media reports. The majority of pharmacists 
expressed difficulty in identifying CFM, as they did not 
rely on the hologram, rather they relied on assessing 
patients’ responses to medicine. 3) CFM reporting 
System; no participants were aware of any reporting 
system, and were not sure how to report suspected CFM. 
4) Prevalence and extent; according to pharmacist 
participants, CFM were mostly prevalent in the northern 
and southern parts of the country (away from the capital) 
and close to the borders where there is less control and 
implementation of regulations due to the current political 
situation. 
Trust 
The four FG participants expressed mistrust and lack of 
faith towards the system and some pharmacists. 1) The 
system; all participants believed that the Ministry of 
Public Health (MoPH) and the Lebanese Order of 
Pharmacists (OPL) were not carrying out their duties as 
should be, such as providing safe and effective medicine. 
Moreover, the public believed that pharmaceutical 
companies are involved in counterfeiting. According to 
pharmacist participants, the distribution channels and 
wholesalers were not well controlled and are not to be 
trusted. This appeared to originate from an incident in 
2010 where CFM were available in some pharmacies 
through legal channels. Therefore, it would be crucial to 
control the supply chain. 2) Pharmacists; a few of the 
public participants believed that going to their trusted 
pharmacist would be one way to avoid buying CFM, the 
others distrusted pharmacists and believed they are all 
involved in the availability of CFM. The majority of 
pharmacist participants emphasized how the few 
pharmacists that were involved in CFM incidents affected 
their image, and how difficult it would be to regain the 
people’s respect and trust. 
Corruption 
All participants expressed their dissatisfaction, and 
believed the government and regulatory authorities were 
manipulating the affairs for private gains. Furthermore, 
participants stressed the weak implementation and 
enforcement of the law, and in their opinion, led to 
diminished border and customs control. The systems’ 
actions were not for the public’s benefit, especially when 
no measures were taken against offenders. Pharmacists 
added that working in such conditions was becoming 
very difficult. 
Overcoming counterfeit medicine 
Participants suggested that responsible authorities should 
use different methods to discourage and stop 
counterfeiters and the public use of CFM. Five subthemes 
emerged: 1) Education; the discussions and exchange of 
experiences among public participants demonstrated the 
need to learn and understand more about CFM and the 
need for authorities to be more transparent. All 
pharmacists believed in their need to be educated and to 
educate patients about CFM. Pharmacists emphasized the 
importance of knowledge, stressing on the ―know how‖ 
that is always missing. The majority of pharmacists 
raised the concern that physicians should also be aware 
and educated regarding CFM, as there seemed to be a 
lack of awareness among physicians. 2) Laws and 
regulations; all participants agreed on the need for laws 
and regulations to be implemented and enforced. In 
addition, there is a need to develop a CFM reporting 
system and a point of reference where the MoPH and 
OPL can be available and involved. 3) Responsibility and 
accountability; the public participants believed that 
naturally the MoPH should be responsible for 
guaranteeing that safe and effective medicine reach all 
pharmacies. They suggested using different methods to 
discourage and stop counterfeiters. 4) Central laboratory; 
all pharmacists highlighted the need for the MoPH to 
reactivate the national laboratory, to randomly test 
samples of medicine in the country. 5) Dedicated 
pharmacists; the majority of pharmacists believed they 
could have a major role in controlling the availability of 
CFM, through organizing and controlling the pharmacy 
profession, to stop the outliers. 
Uncommon themes 
Locus of control 
This theme reflected the degree that public participants’ 
perceived events to be under their control (internal) or 
under the control of others who are more powerful 
(external) as the following subthemes: 1) Internal control; 
participants’ believed that controlling the events and 
outcomes themselves were dependent on their 
knowledge. The majority highlighted that people in 
general lacked enough knowledge about medicine, and 
thus did not know what to do. 2) External control; 
participants’ believed they did not have the power to 
control events or outcomes, rather relying on outside 
influences or external factors such as other people, 
government, or fate. These external factors were 
subdivided into: a) Worries; participants’ worries and 
concerns relating to the outcome of their medicine if 
Sholy LB et al. Int J Community Med Public Health. 2018 Feb;5(2):489-499 
                                International Journal of Community Medicine and Public Health | February 2018 | Vol 5 | Issue 2     Page 496 
counterfeit. b) Financial concern; the high cost of 
medicine was the reason behind the availability of CFM. 
Patients would unknowingly go for a cheaper medicine if 
given a choice. c) Political instability; the majority of 
participants seemed overwhelmed with the country’s 
political instability, and did not consider CFM a priority 
for the government or politicians. Participants considered 
themselves unworthy of ―good‖ medicine. 
Reasons for availability of CFM 
The following subthemes emerged while pharmacists’ 
FGs were describing the reasons for CFM availability: 1) 
Pharmacists; for the following reasons: a) Business and 
profit; the majority believed that there are some unethical 
pharmacists who do not care, and each community has 
pharmacists that deal with CFM, thus contributing to the 
mistrust towards pharmacists. Moreover, some 
pharmacists illegally discounted the medicine priced by 
the MoPH to appear more compassionate towards 
patients, when the discounted medicine may be 
counterfeit. b) Professional experience; participants 
shared their experiences about being approached and 
offered CFM. Participants reported how dealers always 
checked around and offered CFM to those interested, and 
would target new pharmacies, young graduates or the 
inexperienced for their tendency to be more vulnerable 
than others. Older participants stated they were also 
approached when they opened their pharmacies, and due 
to their continuous rejections, were no longer 
approached. 2) Medicine shortages; the majority believed 
that counterfeiters took advantage of medicine shortages 
and offered cheaper alternatives or provided attractive 
offers for medicine that could only be counterfeit. 3) 
Demand; the majority reported in believing that patients 
end up buying CFM due to the high cost of medicine, and 
the financial situation caused by the political instability. 
Participants believed that some members of the public 
may be aware but do not care and choose the cheaper 
medicine (CFM), and some lack awareness. 4) Control; 
participants reported that their concerns were due to the 
MoPH’s lack of control of available medicine and the 
supply chain. Pharmacists expressed that they had limited 
control and were under a lot of pressure. 
 
Figure 1: The structure of the thematic network for the four focus groups. 
 
The structure of the thematic network for the four FG is 
presented in Figure 1. 
Figure 1 shows the thematic network for the four focus 
groups. The themes are divided into contributing factors 
that cause or lead to the availability of counterfeit 
medicine, and the overcoming factors that can limit or 
control their availability. 
DISCUSSION 
The study explored the views, experiences, and beliefs of 
the public and pharmacists towards CFM using FG. The 
study applied the mixed methods methodology using both 
quantitative and qualitative research. Four common 
themes emerged among all participants indicating the 
similar views and beliefs about CFM, reflecting their own 
perceptions and experiences. The discussions showed a 
lack of experience and limited awareness towards CFM 
among the public, however pharmacists were aware but 
the level of expertise appeared related to the number of 
years in practice. The study sample for all groups had an 
over-representation of females, thus the results might be 
gender specific, as studies show that males and females 
do have different views and beliefs.
24
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Contributing factors to CFM 
No participants were aware of the CFM reporting system, 
and considered the pharmacy a reasonable place for 
reporting suspected CFM. One study expressed the 
pharmacists’ need for counselling patients about the 
system and an official CFM reporting system.
13,25
 
Moreover, pharmacists indicated that CFM were more 
prevalent in the North, South, and Bekaa in accordance 
with phase one of the study where the extent of CFM 
ranged from 3% in ML to 12.1% in the South and the 
Bekaa.
11
 The difficulty expressed by participants in 
identifying CFM was supported by other studies on how 
easy it is becoming to counterfeit.
8,11
 
The mistrust towards the MoPH, OPL, pharmacists, 
regulatory authorities and pharmaceutical companies was 
probably due to what participants considered lack of 
transparency and professional misconduct. The findings 
were in accordance with the WHO that counterfeiting 
contributes to damaging the reputation of pharmaceutical 
companies by destroying public confidence and trust in 
their medicine, causing the reluctance of some companies 
to publicize incidents of their products being 
counterfeited.
26
  
The continuous increase in the number of graduating 
pharmacists’ year on year was reported to have decreased 
pharmacists’ minimum wages to $1350/month which 
might have contributed to some pharmacists being 
involved in the reported incidents involving CFM.
13,27
 
Many studies have documented the impact pharmacists 
can play in improving patients’ health outcomes, and 
decreasing the chances of dispensing CFM.
1,5,10,25,28 
However, the good or bad headlines do influence the 
perception of the pharmacy profession, therefore, more 
efforts are required to enhance the reputation of the 
profession, and improve pharmacists’ image to regain the 
public' trust.
29
 
Trust is an important asset the public can give to 
healthcare professionals when their work is for furthering 
social justice and public health.
30
 According to the UK 
code of ethics, the public need to trust that they are 
pharmacists’ primary concern, and that pharmacists are 
honest, trustworthy, and protective of patients from any 
harm by providing safe and effective medicine.
31
 To date, 
there is no known or published code of ethics for 
pharmacists in Lebanon; consequently, the OPL should 
consider agreeing on a code that all registered 
pharmacists must follow.
13
 
The mistrust theme is related to corruption according to a 
study that measured the degree of trust in societies 
around the world, which varied considerably and was 
strongly correlated with views about crime and 
corruption.
32
 The study also reported that 67% of the 
Lebanese respondents disagreed that most people in 
society are trustworthy, compared to Egypt (40%), Jordan 
(45%) and Kuwait (71%). Moreover, the Lebanese and 
Nigerian’s trust was rare due to respondents’ reported 
concern about widespread of political corruption. In fact, 
in countries where people reported trusting each other, 
there were less worries about crime or corrupt political 
leaders.
32
 This study’s participants stated the need for 
clear laws to be implemented and enforced, although they 
did not believe that their suggestions would be 
implemented or would change anything, since corruption 
is so deeply rooted in the culture.
33
 Cultures of 
corruptions will not fade away and according to 
participants, this is the case in Lebanon.
34 
Consequently, the belief that corruption had a role in the 
availability of CFM is also reported in the USA and UK, 
where corruption among wholesalers and illegal supply 
chains allowed CFM to enter their legal chain system.
6,35
 
The problem of medicine shortage in Lebanon is also a 
global concern that counterfeiters take advantage of
8
 by 
using original holograms on counterfeits.
11
 This would 
explain why pharmacists reported not relying on 
holograms.
13 
Furthermore, participants stated that the shortage of 
medicine increases the demand for cheaper medicine that 
are highly likely to be counterfeits, which is supported by 
a number of studies.
1,7,10,36
 In Poland, people who had low 
monthly income found the low cost of CFM attractive, 
and consciously bought them due to their availability and 
low cost, increasing the demand for CFM.
37
  
Overcoming factors to CFM 
Participants also emphasised the need for the government 
to develop legal frameworks and strong legislations 
regulating medicine, with severe penalties to deter 
counterfeiters, as supported by several studies.
1,7,10,17
 
Their suggestions were in support of the OPL with 
pharmacists being positioned at customs and within 
hospitals. There were also further suggestions to 
reactivate the national laboratory to test and control all 
medicines in the Lebanese market and the supply chain, 
to ensure safety.
5,13,38
 
 
All participants indicated that education was key, and 
considered education the turning point for controlling 
CFM availability as supported by other studies.
1,13,39
 
Participants demonstrated the need to establish a 
centralized and standardized reporting system, such as 
Medwatch to encourage voluntary reporting of suspected 
CFM.
40
 The burden of CFM can then be estimated by 
costs of hospitalizations or ambulatory settings for 
treating the consequences of CFM use.
10
 
Identifying the appropriate interventions required for the 
educational, managerial and regulatory programs may 
lead to the development of beneficial interventions.
36
 
Additionally, pharmacists’ awareness and CFM education 
can play a key role in educating and counselling patients 
about CFM that can empower the public by decreasing 
their vulnerability towards CFM, improving detection 
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and reporting of CFM, thus reducing their 
availability/use. 
Limitations 
When approached, not all pharmacists were enthusiastic 
or willing to participate in the study. The FG were 
conducted in ML, the region with the lowest incidences 
of CFM use. There was bias in the sample of public 
participants, as the majority had university degrees, were 
females and were in the same age group. 
CONCLUSION  
This is the first study to generate insight on awareness 
among the public, and pharmacists towards CFM in 
Lebanon. The results were consistent with previous 
studies on the need for changes related to regulations, 
enforcement of the law, and updating pharmacists’ CFM 
knowledge. Additionally, emphasised the role of high 
prices and the unaffordability of medicines in increasing 
vulnerability of the public to using CFM. Finally, there is 
a need for future mixed methods research to assess and 
confirm the themes suggested in this study. 
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